MPP signs on four gener­ics mak­ers to make No­var­tis' Tasigna more ac­ces­si­ble

The Med­i­cines Patent Pool has set up sub­li­cense agree­ments with four man­u­fac­tur­ers to pro­duce gener­ic ver­sions of No­var­tis’ can­cer drug Tasigna, as part of an on­go­ing ef­fort to make ac­cess to med­i­cines more eq­ui­table.

The UN-backed agency an­nounced the news Thurs­day, say­ing that In­di­an gener­ics mak­ers Eu­gia, Het­ero and Dr. Red­dy’s Lab­o­ra­to­ries — along with In­done­sia com­pa­ny Bright­Gene — can man­u­fac­ture and sup­ply gener­ic ver­sions of nilo­tinib, which was first ap­proved by the FDA to treat chron­ic myeloid leukemia in 2007.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER